0
Your cart

Your cart is empty

Browse All Departments
  • All Departments
Price
  • R2,500 - R5,000 (1)
  • -
Status
Brand

Showing 1 - 1 of 1 matches in All Departments

Drug Safety Data: How To Analyze, Summarize And Interpret To Determine Risk (Paperback): Michael J Klepper, Barton Cobert Drug Safety Data: How To Analyze, Summarize And Interpret To Determine Risk (Paperback)
Michael J Klepper, Barton Cobert
R3,114 Discovery Miles 31 140 Ships in 10 - 15 working days

Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk was selected for The First Clinical Research Bookshelf - Essential reading for clinical research professionals by the Journal of Clinical Research Best Practices. Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides drug safety/pharmacovogilance professionals, pharmaceutical and clinical research scientists, statisticians, programmers, medical writers, and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data. The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for pre- and post-marketing risk assessment. With decades of pharmaceutical research and drug safety expertise, authors Dr. Klepper and Dr. Cobert discuss how quality planning, safety training, and data standardization result in significant cost, time, and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is the definitive guide to drug safety data analysis and reporting. Key features include: * Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports * Pragmatic tips...and mistakes to avoid * Simple explanations of what safety data are collected, and what the data mean * Practical approaches to determining a drug effect and understanding its clinical significance * Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical * Examples of user-friendly data displays that enhance safety signal identification * Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting * Relevant material for the required training of drug safety/pharmacovigilance professionals * SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR)

Free Delivery
Pinterest Twitter Facebook Google+
You may like...
Boucheron Quatre Eau De Parfum Spray…
R1,825 Discovery Miles 18 250
Estee Lauder Beautiful Belle Eau De…
R2,241 R1,652 Discovery Miles 16 520
Alcolin Cold Glue (125ml)
R46 Discovery Miles 460
Carbon City Zero - A Collaborative Board…
Rami Niemi Game R656 Discovery Miles 6 560
JBL T110 In-Ear Headphones (Black)
 (13)
R229 R201 Discovery Miles 2 010
Microsoft Xbox Series X Console (1TB…
R14,999 Discovery Miles 149 990
We Were Perfect Parents Until We Had…
Vanessa Raphaely, Karin Schimke Paperback R330 R220 Discovery Miles 2 200
Vital BabyŽ NURTURE™ Breast-Like Feeding…
R259 Discovery Miles 2 590
De'Longhi Coffee Tamper
R449 R349 Discovery Miles 3 490
Stabilo Boss Original Highlighters…
R144 R75 Discovery Miles 750

 

Partners